Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant in girls with progressive precocious puberty associated with McCune-Albright syndrome
2005-004893-26Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in precocious puberty and McCune-Albright syndrome (MAS), sponsored by AstraZeneca. Primary endpoints: Tolerability and safety, Efficacy and 1 more. Status: unknown.
02
Drugs
fulvestrant
03
Conditions
precocious pubertyMcCune-Albright syndrome (MAS)
Beyond the preview
Go deeper on 2005-004893-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004893-26.